|
VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus/minus VCN-01 in patients with metastatic pancreatic cancer. |
| |
|
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; Astellas Pharma; AstraZeneca (I); Bayer; BMS; Boehringer Ingelheim; Esteve; Gilead Sciences (I); Hutchmed; Ipsen; Lilly (I); Merck; Midatech Pharma; Mirati Therapeutics (I); MSD; Pfizer (I); PharmaMar; Roche (I); Sanofi (I); Servier; Takeda |
Research Funding - BMS (Inst); MSD (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis; Esteve; Ipsen; Merck; MSD |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; Arcus Biosciences; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Paraxel; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Zymeworks |
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst) |
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER |
| |
|
Research Funding - Theriva Biologics (Inst) |
Patents, Royalties, Other Intellectual Property - Columbia University, |
Expert Testimony - National Medical Consultants, P.C. |
Travel, Accommodations, Expenses - Merck |
| |
|
Consulting or Advisory Role - Relay Therapeutics |
Speakers' Bureau - Eisai; Seagen |
Research Funding - Astellas Pharma (Inst); EpicentRx (Inst); Erytech Pharma (Inst); Eureka Therapeutics (Inst); FibroGen (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); NGM Biopharmaceuticals (Inst) |
| |
|
Expert Testimony - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca |
| |
|
Employment - Chan Soon-Shiong Institute for Advanced Health; Hoag |
Consulting or Advisory Role - Bayer; ipsen |
Speakers' Bureau - Bayer; Ipsen |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - AstraZeneca (Inst); Boston Scientific (Inst); ERYTECH Pharma (Inst); Ipsen (Inst); Oncosil (Inst); Panbela Therapeutics (Inst); QED Therapeutics (Inst) |
Expert Testimony - Boston Scientific |
Travel, Accommodations, Expenses - AstraZeneca; General Electric; Oncosil; Roche; Sanofi/Aventis |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Abbott (Inst); ESTEVE. (Inst); Fresenius Kabi (Inst); Merck (Inst); Novartis Biociencias (Inst); SERVIER (Inst); Triple AAA (Inst) |
|
Research Funding - NET-FIT ESPAÑA |
| |
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Pfizer; Celgene; Daiichi Sankyo; GlaxoSmithKline; Incyte; LEO Pharma; Lilly; MSD Oncology; Roche; Sanofi; SERVIER |
Speakers' Bureau - Bayer; Menarini; Rovi; SERVIER; STADA |
Research Funding - Celgene; LEO Pharma; Rovi; Sanofi |
Patents, Royalties, Other Intellectual Property - Risk assessment model in venous thromboembolism in cancer patients |
Travel, Accommodations, Expenses - Amgen; Celgene; Merck Serono; Pfizer; Roche; SERVIER |
| |
|
Honoraria - Leo Pharma; SERVIER |
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Novartis; PharmaMar; Roche; SERVIER |
| |
|
Consulting or Advisory Role - Jazz Pharmaceuticals; Kanaph Therapeutics; OncXerna Therapeutics; SOTIO |
Research Funding - Bayer (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Pfizer (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Tolero Pharmaceuticals (Inst); Yingli Pharma (Inst) |
| |
|
Employment - THERIVA BIOLOGICS INC. |
Stock and Other Ownership Interests - THERIVA BIOLOGICS INC. |
| |
|
Employment - Theriva Biologics, Inc. |
Stock and Other Ownership Interests - Theriva Biologics, Inc. |
| |
|
Employment - THERIVA BIOLOGICS INC.; THERIVA BIOLOGICS INC. (I) |
Leadership - THERIVA BIOLOGICS INC. (I) |
Stock and Other Ownership Interests - THERIVA BIOLOGICS INC. (I) |
| |
|
Employment - Theriva Biologics |
Stock and Other Ownership Interests - Theriva Biologics |
| |
|
Employment - Theriva Biologics SL |
Leadership - Theriva Biologics SL |
Stock and Other Ownership Interests - THERIVA BIOLOGICS INC.; THERIVA BIOLOGICS INC. (I) |
Patents, Royalties, Other Intellectual Property - Theriva Biologics SL |
| |
|
|
Stock and Other Ownership Interests - Champions Oncology; InxMed; Nelum Corp. |
Honoraria - Champions Oncology; InxMed; MiNK Therapeutics; Oncomatrix |
Consulting or Advisory Role - Fibrogen; InxMed; KAHR Medical; MiNK Therapeutics; Oncomatrix |
Research Funding - Ranok Therapeutics; TopAl |
Patents, Royalties, Other Intellectual Property - Royalties from Khar Medical for IP in cell therapy; Royalties from Myriad for PALB2 patent |
Travel, Accommodations, Expenses - Agenus |